Inclusion Criteria:~1. Signed an Institutional Review Board (IRB) approved informed consent document~2. Aged 50
- 89 years inclusive.~3. Meeting the diagnosis of probable AD consistent with:~ * Revised National Institute on
Aging-Alzheimer's Disease Association (NIA-ADA) criteria and~ * Diagnostic and Statistical Manual of Mental
Disorders (DSM IV) criteria.~4. Mild to severe severity (Mini-Mental Status Exam \[MMSE\] scores 7 - 24
inclusive).~5. Rosen-Modified Hachinski Ischemia Score of ≤4.~6. Have a suitable caregiver to supervise the
at-home administration of study drugs and observe for AEs.~7. Patients treated with donepezil 5 or 10 mg/day
(given once daily) for at least 4 weeks just prior to Day1 for Population (group) 1 or;~8. Patients never been
treated with donepezil before (donepezil naÃ¯ve) or who have not received any other AChEI for the past 6 months
for Population (group) 2.~9. Patients in generally good health as indicated by their medical history and
physical examination, vital signs, electrocardiogram (ECG), and standard laboratory tests.~
